(Boursier.com) — MaaT Pharma takes stock of its activities and the main milestones expected in 2024:
*Positive efficacy and safety data of MaaT013 in aGvHD in the Compassionate Access Program presented at the EBMT 2024 Annual Conference with a gastrointestinal overall response rate (GI-ORR) of 63% at D28, an overall survival (OS) of 49% at one year and 42% at 18 months in patients similar to those included in the Phase 3 ARES clinical trial.
*The primary endpoint, GI-ORR at D28, of the ARES Phase 3 clinical trial in aGvHD is expected in mid-Q4 2024.
*Production of batches of MaaT013 intended for clinical supply in the United States.
*Participation in an investigator-sponsored, randomized, multicenter Phase 2 trial evaluating MaaT033 concomitantly with anti-PD1 therapy in patients with advanced lung cancer. This trial, promoted by the Gustave Roussy Institute which pilots cutting-edge research in the field of microbiota, is part of the IMMUNOLIFE program, a consortium comprising researchers and biotechnology companies.
*Completion of patient recruitment for the IASO Phase 1 clinical trial, evaluating MaaT033 in patients with amyotrophic lateral sclerosis (ALS).
Hervé Affagard, CEO and co-founder of MaaT Pharma, said: “We are moving forward with confidence towards the Phase 3 results for MaaT013, while continuing to achieve key milestones and create value for shareholders. Recent data presented at the EBMT annual congress highlighted the potential of MaaT013 in aGvHD, where therapeutic options are insufficient. We are also proud to partner with the Institut Gustave Roussy (IGR), a globally recognized center in the field. cancer treatment, in order to explore the impact of MaaT033 on the response to immune checkpoint inhibitors in patients with non-small cell lung cancer and thus deepen our development in immuno-oncology. This collaboration reinforces. the leading position of MaaT Pharma in oncology and the interest of the medical community in drug candidates derived from the microbiota”.
©2024 Boursier.com